Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|S3|S123-S132

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.S3, 2015-03, pp. : S123-S132

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Expert perspectives on biosimilar monoclonal antibodies in breast cancer

By Cortés J.   Curigliano G.   Diéras V.  

Breast Cancer Research and Treatment, Vol. 144, Iss. 2, 2014-04 ,pp. : 233-239

Springer Publishing Company

Access to resources Recommend Favorite

Monoclonal Antibodies - Regulatory Challenges

By  

Current Pharmaceutical Biotechnology, Vol. 9, Iss. 6, 2008-12 ,pp. : 431-438

Bentham Science Publishers

Access to resources Recommend Favorite

Detection of Clinically Relevant Antibodies Pretransplant and Posttransplant With PRA-STAT

By anti-CD45 study group   Neylan J.   de Smet W.   Stijlemans B.   Brinker K.   Gonwa T.   Moran J.   Segers A.  

Transplantation Proceedings, Vol. 29, Iss. 1, 1997-02 ,pp. : 330-332

Elsevier

Access to resources Recommend Favorite

Monoclonal Antibodies and Toxins—A Perspective on Function and Isotype

By Chow Siu-Kei   Casadevall Arturo  

Toxins, Vol. 4, Iss. 6, 2012-06 ,pp. : 430-454

MDPI

Access to resources Recommend Favorite

Considerations for Improving High to Low Dose Extrapolation for Regulatory Risk Assessment

By Zeise Lauren  

Human and Ecological Risk Assessment, Vol. 13, Iss. 1, 2007-01 ,pp. : 57-69

Taylor & Francis Ltd

Access to resources Recommend Favorite